CCM
ABBV icon

Copernicus Capital Management’s AbbVie ABBV Stock Holding History

Copernicus Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,000
Closed -$649K – 12
2021
Q1 		$649K Buy
6,000
+1,324
+28% +$142K 10.49% 4
2020
Q4 		$501K Sell
4,676
-143,763
-97% -$13.8M 7.81% 4
2020
Q3 		$13M Buy
148,439
+38,439
+35% +$3.62M 12.38% 1
2020
Q2 		$10.8M Buy
+110,000
New +$9.69M 11.84% 1
2020
Q1 		– Sell
-76,957
Closed -$6.81M – 15
2019
Q4 		$6.81M Sell
76,957
-55,043
-42% -$4.57M 8.93% 5
2019
Q3 		$9.99M Buy
+132,000
New +$9.05M 9.3% 4

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Copernicus Capital Management's ABBV Position: Q2 2021 in Review

Copernicus Capital Management sold out of AbbVie (ABBV) in Q2 2021, closing a stake of 6,000 shares — an estimated $649K sold.

Copernicus Capital Management first reported a position in ABBV in Q3 2019 and held it in 6 quarters. The position peaked at $13M in Q3 2020. 2,676 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.

  • Copernicus Capital Management reported no remaining AbbVie position as of Q2 2021 after selling out during the quarter.
  • Copernicus Capital Management sold 6,000 AbbVie shares in Q2 2021, an estimated $649K.
  • Copernicus Capital Management first reported a position in AbbVie in Q3 2019 and held it in 6 quarters.
  • Copernicus Capital Management's AbbVie position peaked at $13M in Q3 2020.
  • 2,676 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.

Based on Copernicus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.